Condition (MeSH)
Hepatitis D, Chronic
ClinicalTrials.gov lists 35 trials for Hepatitis D, Chronic or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
35 of the 35 trials are tagged with Hepatitis D, Chronic itself; the rest are tagged with a narrower condition beneath it.
When did Hepatitis D, Chronic trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 3 |
| 2017 | 1 |
| 2016 | 3 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 32 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 16 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hepatitis D, Chronic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 8 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 8 |
How many Hepatitis D, Chronic trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 6 |
| Completed | 15 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hepatitis D, Chronic trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 4 |
| Vir Biotechnology, Inc. | 4 |
| Gilead Sciences | 3 |
| EIT Pharma, Inc. | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Hepatitis D, Chronic? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Bulevirtide | 6 |
| VIR-3434 | 4 |
| VIR-2218 | 4 |
| Lonafarnib | 3 |
| PEGinterferon alfa-2a | 3 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ritonavir (RTV) low | 3 |
| Liver biopsy | 1 |
| Peginterferon Lambda | 1 |
| pegylated IFN alfa-2b plus ribavirin | 1 |
| GS-4321 | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hepatitis D, Chronic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hepatitis D | 10 | 1 |
| jaundice | 6 | 1 |
| Covid-19 | 5 | 2 |
| Covid-19 pneumonia | 5 | 2 |
| Urinary tract infection | 3 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hepatitis D, Chronic? (33)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D. | The New England journal of medicine | 2026 | Yes |
| Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy. | United European gastroenterology journal | 2026 | Yes |
| Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States. | Journal of viral hepatitis | 2026 | Yes |
| Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. | Liver international : official journal of the International Association for the Study of the Liver | 2025 | Yes |
| Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide. | Journal of hepatology | 2025 | Yes |
Showing 5 of 33 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.